SEC Form 20-F filed by Zhengye Biotechnology Holding Limited
$ZYBT
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)
Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced the implementation of a dual-class share structure, effective April 7, 2026. At the annual general meeting of shareholders held on March 24, 2026, the Company's shareholders approved the introduction of two classes of ordinary shares, designated as Class A and Class B. The Company's Class A ordinary shares are expected to begin trading on the Nasdaq Capital Market at the open of
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that Mr. Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. In the letter, Mr. Han highlights the Company's research and operational milestones achieved in 2025 and outlines Zhengye's strategic priorities for growth in 2026. The full text of the letter follows. Dear Shareholders, As we enter 2026, on behalf of the management of Zhengye
JILIN, China, July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2024. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2024 was a transformational year for us, marked by strategic decisions and tough yet necessary shifts, as we navigated significant market adjustments and proactively diversified our customer base in pursuit of long-term growth. Amid global un
6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)
6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)
20-F - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)